Natalizumab (Anti-CD49d)
Based on 3 publication(s) in Google Scholar
Natalizumab (Anti-CD49d) (AN100226; BG00002) Solution is a humanized monoclonal IgG4 antibody inhibitor that selectively targets α4 integrin (CD49d), blocking the interaction of integrins such as α4β1 (VLA-4) with vascular cell adhesion molecule VCAM-1, intercellular adhesion molecule ICAM-1, and fibronectin by competitively binding to the α4 subunit. Natalizumab solution inhibits the adhesion, retention, and transendothelial migration of immune cells (such as CD4+ T cells), reducing the infiltration of inflammatory cells into the central nervous system or lesion sites, thereby exerting anti-inflammatory and immunomodulatory activity. Natalizumab (Anti-CD49d) solution is used in the study of relapsing-remitting multiple sclerosis (RRMS) and is also applied in the research of autoimmune or inflammation-related diseases such as Crohn's disease, B-cell lymphoma, and non-infectious uveitis. Natalizumab (Anti-CD49d) can also prevent lymphocytes from entering the central nervous system, thus preventing acute demyelinating relapses.
For research use only. We do not sell to patients.
- Purity: 99.71%
- CAS No.: 189261-10-7
- Molecular Weight:146.22 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Natalizumab (Anti-CD49d)
More
Biological Activity
Human IgG4 kappa
Human
ITGA4
Natalizumab (Anti-CD49d) (10 μg/mL, 2 h) reduced the adhesion of VLA-4-positive lymphoma cells (Raji, Karpas-422, etc.) to fibronectin by 75-95% and altered cell adhesion morphology[2].
Natalizumab (Anti-CD49d) (10 μg/mL in combination with rituximab) partially overcame the protective effect of bone marrow stromal cells on lymphoma B cells, mitigating resistance to apoptosis induced by Rituximab (HY-P9913) and cytotoxic drugs[2].
Natalizumab (Anti-CD49d) (30 μg/mL) slightly upregulated the expression of IL-2, IFN-γ, and IL-17 in activated CD4+ T cells, triggered MAPK/ERK phosphorylation, and downregulated CD49d surface expression[3].
Natalizumab (Anti-CD49d) (1 μg/mL) alone could not significantly inhibit the retention of CD4+ T cells or PBMCs in an inflammatory state BBB model (BLEC, HBMEC, etc.), requiring co-inhibition of β2-integrin for complete blockade[1].
Natalizumab (Solution) (1 μg/mL) was ineffective in inhibiting shear-resistant retention of CD4+ Th1 cells when the molar ratio of ICAM-1 to VCAM-1 was 10:1[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Natalizumab (Anti-CD49d) (170 μg/mouse; intravenous injection; single dose) only partially and transiently reduced the firm adhesion of human T cells to the activated BBB in a TNF-α-induced acute systemic inflammation model in female SJL mice, significantly reducing T cell rolling along the vessel wall but not affecting capture[4].
Natalizumab (Solution) (0.625-2.5 mg/mouse; intravitreal injection; single dose; 21-day observation period) showed no functional or structural toxicity to the retina of New Zealand white rabbits at doses of 0.625-1.25 mg, with no significant changes in the amplitude and latency of a-wave and b-wave in electroretinogram (ERG), but the 2.5 mg dose caused retinal dysfunction, with significantly reduced a-wave and b-wave amplitudes in ERG, and ultrastructural damage in the outer plexiform layer and inner nuclear layer[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
IgG4-kappa
ELISA, FACS, Functional assay
-
Flow cytometric analysis of 1X106 Jurkat cells with Natalizumab (Solution) (HY-108831A, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Fluor 488-conjugated AffiniPure Goat Anti-Human IgG H&L (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG4 (S228P) kappa Isotype Control (HY-P99003, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
Chemical Information
-
CAS No. 189261-10-7
-
Appearance Liquid
-
Molecular Weight 146.22 kDa
-
Color Colorless to light yellow
-
SMILES
[Natalizumab (Anti-CD49d)]
-
Synonyms
AN100226; BG00002
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
Mol Med
2024 Apr 22;30(1):54. PMID: 38649802 -
Pharmaceutics
LPX-TI641, a Tim3/4 Agonist, Induces Long-Term Immune Tolerance in Multiple Sclerosis Models. [Abstract]2025 Oct 30;17(11):1402. PMID: 41304740 -
Purity & Documentation
-
Data Sheet (265 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Soldati S, et al. High levels of endothelial ICAM-1 prohibit natalizumab mediated abrogation of CD4+ T cell arrest on the inflamed BBB under flow in vitro. J Neuroinflammation. 2023 May 23;20(1):123. [Content Brief]
[2]. Mraz M, et al. Bone marrow stromal cells protect lymphoma B-cells from rituximab-induced apoptosis and targeting integrin α-4-β-1 (VLA-4) with natalizumab can overcome this resistance. Br J Haematol. 2011 Oct;155(1):53-64. [Content Brief]
[3]. Benkert TF, et al. Natalizumab exerts direct signaling capacity and supports a pro-inflammatory phenotype in some patients with multiple sclerosis. PLoS One. 2012;7(12):e52208. [Content Brief]
[4]. Coisne C, et al. Cutting edge: Natalizumab blocks adhesion but not initial contact of human T cells to the blood-brain barrier in vivo in an animal model of multiple sclerosis. J Immunol. 2009 May 15;182(10):5909-13. [Content Brief]
[5]. Chawla R, et al. An experimental study to evaluate safety/toxicity of intravitreal natalizumab. Indian J Ophthalmol. 2018 Oct;66(10):1441-1445. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz